全身[68Ga]Ga-PSMA-11 PET/CT在前列腺癌中的临床价值:识别区域外骨转移并指导治疗策略
本研究回顾性纳入1211例接受全身[68Ga]Ga-PSMA-11 PET/CT的前列腺癌患者,评估传统视野(CFOV)范围外骨转移的患病率及其对肿瘤负荷、分期和治疗的影响。结果显示5.12%患者存在CFOV外骨转移,CRPC分期、Gleason评分≥8和PSA≥12.57 ng/mL为独立预测因素,且32.3%的该亚组患者治疗方案发生改变。
要点
- 全身[68Ga]Ga-PSMA-11 PET/CT可发现5.12%前列腺癌患者存在CFOV外骨转移。
- CRPC分期、Gleason评分≥8和PSA≥12.57 ng/mL是CFOV外骨转移的独立预测因素。
- CFOV外病变使肿瘤负荷指标显著增加(P<0.001),并导致32.3%亚组患者治疗改变。
核心结论
- 短轴视野PET/CT的传统扫描范围可能低估骨转移真实范围,全身扫描可发现约5%的隐匿性CFOV外骨转移并影响治疗决策。
研究设计与样本
- 回顾性研究纳入1211例接受全身[68Ga]Ga-PSMA-11 PET/CT的前列腺癌患者,图像由三名核医学医师独立评估,阳性发现经组织病理学、治疗反应、PSA变化或随访影像验证。
主要发现
- 1211例患者中5.12%(62例)存在CFOV外骨转移,除骨转移外未发现CFOV外其他类型病变。
- 多变量回归显示CRPC分期、Gleason评分≥8和PSA≥12.57 ng/mL是CFOV外骨转移的独立预测因素。
- 在62例CFOV外病变患者中,肿瘤负荷指标PSMA-TV和TL-PSMA显著增加(P<0.001)。
- 20例患者(该亚组的32.3%,总队列的1.65%)因全身扫描改变治疗方案。
- 构建的列线图中疾病分期对CFOV外骨转移的预测价值大于Gleason评分和PSA水平。
关键数值与推荐
- CFOV外骨转移定义为远端至股骨近端三分之一的骨转移。
- CFOV外骨转移患病率为5.12%(62/1211)。
- 独立预测因素包括CRPC分期、Gleason评分≥8和PSA≥12.57 ng/mL。
- 肿瘤负荷指标PSMA-TV和TL-PSMA在CFOV外病变亚组中显著增加(P<0.001)。
- 治疗改变发生于32.3%的CFOV外病变亚组(1.65%总队列)。
临床怎么用
- 对于具有CRPC分期、高Gleason评分或高PSA的前列腺癌患者,可考虑使用全身PET/CT扫描范围以发现CFOV外骨转移。
- 列线图可帮助配备短轴视野PET/CT的中心的临床医生识别最可能从扩大视野成像中获益的患者。
- 发现CFOV外骨转移可导致疾病分期上调并影响治疗计划。
局限性
- 本研究为回顾性设计。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Bone metastasis significantly impacts morbidity and mortality in prostate cancer patients, necessitating accurate detection and monitoring. Although [68 Ga]Ga-PSMA-11 PET/CT imaging provides superior sensitivity compared with conventional imaging, the conventional field of view (CFOV; skull to proximal femur) obtained with short axial field of view (SAFOV) PET/CT scanners may underestimate the extent of disease. This study aimed to evaluate the prevalence and characteristics of bone metastases outside the CFOV scan range (distal to the proximal one-third of the femur) using total-body [68 Ga]Ga-PSMA-11 PET/CT imaging and its impact on tumor burden, staging and subsequent treatment in prostate cancer patients. METHODS: This retrospective study included 1211 prostate cancer patients who underwent total-body [68 Ga]Ga-PSMA-11 PET/CT imaging. Imaging results were independently evaluated by three nuclear medicine physicians. Positive findings were validated through histopathology, treatment response, prostate-specific antigen (PSA) changes, or follow-up imaging. We further characterized the clinical and imaging characteristics of lesions located beyond the CFOV scan range. We also assessed the impact of total-body imaging on tumor burden biomarkers (PSMA-TV and TL-PSMA) and disease staging, and constructed a nomogram to predict the risk of extra-CFOV lesions. RESULTS: Apart from bone metastases, total-body [68 Ga]Ga-PSMA-11 PET/CT imaging did not identify any other types of lesions outside the CFOV scan range. Among the 1211 patients, 5.12% (62 patients) had bone metastases outside the CFOV scan range. Multivariable regression analysis revealed that patients in the castration-resistant prostate cancer (CRPC) stage, with higher Gleason scores (≥ 8), and higher PSA levels (≥ 12.57 ng/mL) were independent predictors of bone metastases outside the CFOV scan range. We developed a nomogram to predict bone metastases outside the CFOV scan range, in which the patient's disease stage demonstrated greater predictive value than the Gleason score and PSA level. In the subset of 62 patients with lesions outside the CFOV scan range, tumor burden metrics were significantly increased (P < 0.001). Treatment plans were altered in 20 patients (32.3% of the subgroup; 1.65% of the total cohort). CONCLUSIONS: SAFOV PET/CT scanners with CFOV scan range may underestimate the true extent of bone metastasis. Total-body scan range using total-body PET/CT scanners revealed occult bone metastases in 5.12% of patients, particularly in those with higher PSA, Gleason scores, and CRPC stage. This extended view significantly impacts tumor burden quantification, leads to disease upstaging, and influences treatment planning. The developed nomogram can guide clinicians at centers with SAFOV PET/CT scanners in identifying patients who would most benefit from extended field-of-view imaging.
引用
- Chen Q, Wang W, Wang Y, et al. The clinical utility of total-body [68 Ga]Ga-PSMA-11 PET/CT in prostate cancer: identifying extra-regional bone metastases and informing treatment strategies. Eur J Nucl Med Mol Imaging. 2025. PMID: 41051535. doi:10.1007/s00259-025-07581-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。